INTRODUCTION
Modified vaccinia virus Ankara (MVA) is an attenuated strain of vaccinia virus (Mayr & Munz, 1964) . Because of its avirulence found following inoculation of animals and its striking deficiency in producing substantial amounts of new viral progeny in most cells of mammalian origin, MVA can be used under laboratory conditions of biosafety level 1 (Mayr et al., 1975; Meyer et al., 1991; Carroll & Moss, 1997; Drexler et al., 1998) . MVA serves as an efficient vector virus for expression of recombinant genes (Sutter & Moss, 1992 , 1995 and as a candidate recombinant vaccine (Moss et al., 1996) with a high safety profile, since MVA has been tested for pre-immunization in over 100 000 humans being vaccinated against smallpox without causing notable side effects (Stickl et al., 1974; Mayr et al., 1978) . Several MVA vector vaccines have already entered clinical evaluation (Corona Gutierrez et al., 2002; Cosma et al., 2003; McConkey et al., 2003; Rochlitz et al., 2003) . Most recently, MVA was reassessed as a candidate second-generation vaccine against smallpox in comparison with immunization with conventional vaccinia virus strains (Belyakov et al., 2003; Drexler et al., 2003; Earl et al., 2004; Wyatt et al., 2004) .
MVA was obtained by long-term serial passage in chicken embryo fibroblast (CEF) tissue cultures, which resulted in much loss of genomic information, including many genes regulating virus-host interactions (Meyer et al., 1991; Antoine et al., 1998) . The MVA homologues of genes encoding recognized poxvirus immune-evasion molecules (reviewed by Moss & Shisler, 2001; Alcami, 2003) including the viral IFN type I and type II receptors, the interleukin 1b (IL1b) converting enzyme inhibitor SPI-2, the vaccinia complement-binding protein, the vaccinia semaphorin, the 35 kDa chemokine-binding protein and the tumour necrosis factor (TNF)-a receptor are deleted or fragmented. Interestingly, some viral genes with immunomodulatory function are maintained in the MVA genome and their possible relevance for the use of MVA-based vaccines remains to be determined. One such example is the coding sequence for the viral IL1b receptor (IL1bR), which is highly conserved in the MVA genome (Antoine et al., 1998) , and expression of IL1bR in MVA-infected cells has been described (Blanchard et al., 1998) . IL1 is a cytokine that plays an important role in the regulation of inflammatory processes and the host innate immune response against infectious agents (reviewed by Sims, 2002) . In contrast to its cellular counterpart, soluble viral IL1bR has a specific affinity only for IL1b (Alcami & Smith, 1992) , the major endogenous pyrogen (Alcami & Smith, 1996) . During vaccinia virus infection of mice, IL1bR was shown to prevent fever by interaction with IL1b. Furthermore, deletion of the IL1bR gene in vaccinia virus accelerated the appearance of symptoms of illness and mortality in intranasally infected mice, suggesting that the blockade of IL1b by vaccinia virus can diminish the systemic acute-phase response to infection and modulate the severity of the disease (Alcami & Smith, 1996) . In contrast, virulence was reduced following intracranial infection of mice with IL1bR-deficient vaccinia virus, possibly reflecting a beneficial role of IL1b on brain-tissue infection (Spriggs et al., 1992) . Therefore, the viral IL1bR gene represents an interesting target for molecular engineering in the search for optimized vaccinia viruses as candidate second-generation vaccines. Here, we evaluated the effects of deletion of the IL1bR gene from the MVA genome. The construction of an MVA IL1bR deletion mutant allowed us to analyse the significance of IL1bR synthesis following in vitro and in vivo infection with MVA. Our data suggested that inactivation of the IL1bR gene may be beneficial for the development of future MVA vaccines.
METHODS
Viruses and cells. Vaccinia virus strain Western Reserve was originally provided by Bernard Moss (NIH, Bethesda, USA), vaccinia virus strains CVA and MVA were originally obtained from Anton Mayr (University of Munich, Germany), and CVA from the second and MVA from the 582nd passage on CEFs (cloned isolate F6) were used for this study. All viruses were propagated and titrated following a standard methodology (Moss & Earl, 1991) . To generate vaccine preparations, viruses were routinely purified by ultracentrifugation through sucrose and reconstituted in 1 mM Tris/HCl, pH 9?0. Primary CEFs and rabbit kidney RK-13 (ATCC CCL-37) cells were grown in minimal essential medium (MEM) supplemented with 10 % fetal bovine serum (FBS) and maintained at 37 uC and 5 % CO 2 .
Plasmids. The transfer plasmid pDK1L-184R carries two DNA fragments that represent flanking sequences of MVA ORF 184R (nt 162021-163001, GenBank accession no. U94848) that have been inserted into multiple cloning sites 1 and 2 of plasmid pDK1L (Staib et al., 2000) . One fragment, designated flank 184R-I, consists of a 486 bp MVA DNA sequence starting in the 59-intergenic region of ORF 184R and ending at the start codon for translation of ORF 184R; the other fragment, flank 184R-II, is a 544 bp PCR fragment of MVA DNA extending from the codon for 184R translation termination into the 39-intergenic region of the 184R gene.
Genetic modification of MVA. Mutant MVAs were obtained following the transient K1L-based host-range selection protocol as described previously (Staib et al., 2000; . Briefly, for the generation of deletion mutant viruses, monolayers of 1610 6 confluent CEFs were infected with MVA at an m.o.i. of 0?01 infectious units (IU) per cell. At 90 min post-infection (p.i.), cells were transfected with 1?5 mg plasmid pDK1L-184R DNA using FuGENE (Roche) as recommended by the manufacturer. At 48 h p.i., transfected cells were harvested and plated on RK-13 cell monolayers for growth selection. Mutant viruses were isolated by plaque cloning on RK-13 cells and then passaged on CEF cells to remove the selectable marker gene K1L. For control purposes, we generated revertant virus MVA-IL1bRev using a standard methodology , reinserting a DNA fragment comprising the complete IL1bR gene sequence under the transcriptional control of its authentic promoter at the site of deletion VI (depicted in Fig. 1 ) into the genome of MVA-DIL1bR.
Analysis of viral DNA by PCR and Southern blotting.
Genomic viral DNA was isolated from infected CEFs as described previously and analysed by PCR using oligonucleotides annealing within the flanking regions flank 184R-I and -II, respectively (primer pair 1) (Staib et al., 2000) or within flanking sequences of deletion site VI in the MVA genome (primer pair 2: Del-VI-59, 59-CCTGGACATTTAGTTTGAGTGTTCCTGAAT-39, and Del-VI-39, 59-CTCAGCATCTAGTTGATATTCCAACCTCTT-39). Specific DNA fragments were amplified by 30 cycles of PCR at an annealing temperature of 52 uC (pair 1) or 55 uC (pair 2).
Alternatively, total DNA isolated from virus-infected cells was digested with EcoRI, separated by gel electrophoresis in 0?8 % agarose, transferred to a Hybond-N membrane (Amersham) and hybridized to a DNA probe consisting of a PCR fragment from flank 184R-I sequences labelled with [a-32 P]dCTP. Prehybridization and hybridization were performed according to Sambrook et al. (1989) . Blots were exposed to a Kodak BioMax film.
Radioimmunoprecipitation of virus-infected cell lysates. CEF cells grown in six-well tissue culture plates were infected with MVA at an m.o.i. of 20 IU per cell. At 6 h p.i., the virus inoculum was replaced with methionine-free MEM containing 5 % FBS and 50 mCi (1?85 MBq) [
35 S]methionine ml 21 and incubated for a further 2 h at 37 uC. Cells were lysed in RIPA buffer containing 0?15 M NaCl, 0?01 M Tris/HCl pH 7?4, 1 % NP-40, 0?1 % SDS, 1 % sodium deoxycholate, 1 mM PMSF and incubated for 16 h at 4 uC with 50 % protein A-Sepharose coupled to rabbit polyclonal anti-B15R antibody (Alcami & Smith, 1992) . Immune complexes were washed in RIPA buffer, dissolved in Laemmli buffer and proteins were separated by 10 % SDS-PAGE.
Analysis of virus growth. To determine low-or high-multiplicity growth profiles, confluent CEF monolayers (grown on six-well plates) were infected with 0?05 or 10 IU MVA or mutant MVA per cell, respectively. After virus adsorption for 60 min at 37 uC, the inoculum was removed. Cells were washed twice with RPMI 1640 and incubated with fresh RPMI 1640 containing 10 % FBS at 37 uC and 5 % CO 2 . At multiple time points p.i., infected cells were harvested and virus was released by freeze-thaw and brief sonication. Virus titres were determined following standard procedures, as described previously (Hornemann et al., 2003) .
Cellular vaccinia virus responses. For ex vivo monitoring of peptide-specific acute-and memory-phase CD8 + T-cell responses, splenocytes from vaccinia virus-immunized HHD mice were prepared and incubated for 5 h with HLA-A*0201-binding peptide (VP35#1; Drexler et al., 2003) at 10 26 M. After 2 h, brefeldin A was added at a final concentration of 1 mg ml 21 (GolgiPlug; BD Biosciences Pharmingen). Splenocytes were live/dead stained with PBS containing 1 % BSA and 1 mg ethidium monoazide bromide (EMA; Molecular Probes) ml 21 and blocked for non-specific FccIII and -II receptor-mediated binding with 5 mg purified anti-CD16/ CD32 (Fc Block; BD Biosciences Pharmingen) ml 21 for 20 min at 4 uC. Cell-surface staining was performed with phycoerythrin (PE)-conjugated anti-CD8 (clone 53-6.7) and allophycocyanin (APC)-conjugated anti-CD62L (clone Mel-14) for 30 min at 4 uC. After permeabilization of cells (Cytofix/Cytoperm kit; BD Biosciences Pharmingen), intracellular cytokine staining was performed for 30 min at 4 uC using FITC-conjugated anti-IFN-c (clone XMG1.2) or FITC-conjugated anti-TNF-a (clone MP6-XT22) or the respective FITC-labelled IgG1 isotype control (clone R3-34) (all from BD Biosciences Pharmingen). Splenocytes were analysed by four-colour flow cytometry (FACSCalibur) using CellQest software (both from Becton Dickinson). For detection of ex vivo vaccinia virus-specific total CD8 + T-cell responses, a fraction of the splenocytes, isolated from HHD or C57BL/6 mice 6 months after vaccination, was infected for 7 h with MVA prior to the addition of brefeldin A. After a further incubation for 16 h, cells were stained and analysed as described above. Statistical analysis (f-or t-test) was performed using GraphPad Prism 4 software. Vaccination experiments were performed at least three times.
Animal models. Female 6-8-week-old transgenic HHD +/+ b 2 m 2/2 D b2/2 mice (HHD) (Pascolo et al., 1997) or female 6-8-week-old BALB/c or C57BL/6 mice were used for vaccination experiments. HHD mice were inoculated with 0?25 ml virus vaccine by the intraperitoneal route and monitored for HLA-A*0201-restricted T-cell responses at days 10 and 180 post-immunization. For protection assays, animals were vaccinated once with 0?03-0?25 ml virus vaccine given by the intranasal or intraperitoneal route. At 3-6 months post-immunization, animals were anaesthetized, infected intranasally with vaccinia virus Western Reserve (10 7 p.f.u. diluted in 30 ml PBS) and monitored for at least a further 3 weeks for morbidity and mortality, with daily measurement of individual body weights and scoring of signs of illness as described previously (Alcami & Smith, 1996) . Animals suffering from severe systemic infection and having lost >30 % body weight were sacrificed. The mean change in body weight was calculated as the percentage of the mean weight for each group on the day of challenge. Body temperature was determined with an Electronic Laboratory Animal Monitoring System (BioMedic Data Systems) using subcutaneously implanted microchip battery-free transponders and a DAS-5004 Pocket Scanner for data collection. Mean changes in body temperature were calculated by subtracting the pre-challenge (days 23 to 0) baseline temperature of each group from each subsequent time point. Experiments in animal models were performed at least twice.
RESULTS

Deletion of IL1bR coding sequences from the MVA genome
In order to analyse the possible role of IL1bR gene expression during MVA infection, we constructed MVA knockout mutants lacking ORF 184R (IL1bR). The coding sequences of viral IL1bR together with its presumed promoter sequence are well conserved within the MVA genome. As with the previously characterized IL1bR of vaccinia virus strain Western Reserve, the predicted MVA polypeptide consists of 326 aa with an identity level of 99 % (Alcami & Smith, 1992; Spriggs et al., 1992; Antoine et al., 1998) . Using PCR, we amplified DNA segments located up-and downstream of the 184R coding sequence and inserted these fragments into the deletion vector pDK1L (Fig. 1) , which contains the vaccinia virus K1L gene as a selectable marker. Following transfection of MVA-infected cells with pDK1L-184R, the 184R flanking regions allowed introduction of the K1L marker gene and simultaneous deletion of the IL1bR gene sequence in the MVA genome by homologous recombination. The resulting viruses were selected on RK-13 cells, where K1L function is essential for MVA growth. After isolation of clonally pure mutant viruses, the K1L marker cassette was removed following passage on CEF cells, yielding the final mutant virus MVA-D IL1bR (Fig. 1) .
Molecular characterization and unimpaired in vitro replication of mutant virus MVA-DIL1bR
After isolation of the MVA deletion mutants, we first wished to confirm the correct removal of IL1bR coding sequences at the genetic level. We analysed viral DNA extracted from CEFs infected with wild-type, mutant or IL1b-revertant MVA (MVA-IL1b-Rev) by PCR using oligonucleotide primers specific for MVA genomic sequences adjacent to the IL1bR gene locus or specific for the site of deletion VI within the MVA genome, the insertion site of the reintroduced IL1bR gene in MVA-IL1b-Rev (Fig. 2a) . The IL1bR gene-specific PCR specifically amplified a 2?1 kb DNA fragment from wild-type templates, whereas the use of DNA from MVA-DIL1bR and revertant MVA-infected cells generated 1?1 kb PCR products corresponding to the expected reduction in size after deletion of ORF 184R. PCR analysis specific for MVA sequences at the site of deletion VI revealed the expected 306 bp DNA fragments for MVADIL1bR and MVA DNA, whereas the use of genomic DNA from revertant virus resulted in amplification of a 1?6 kb DNA fragment, suggesting the correct insertion of the complete IL1bR gene expression cassette. Furthermore, we digested viral DNAs with restriction endonuclease EcoRI and revealed DNA fragments containing the IL1bR gene locus by Southern blot analysis. Confirming the PCR data, we detected a 6500 bp EcoRI fragment in the genomic DNA of deletion mutant MVA-DIL1bR compared with a 7800 bp MVA DNA fragment (Fig. 2b) , corresponding to the expected loss of 1?3 kb and again verifying correct deletion of the targeted ORF 184R sequences.
The IL1bR protein is produced during MVA infection (Blanchard et al., 1998) and we wished to demonstrate that the generated mutants failed to synthesize this polypeptide and that expression was restored following infection with MVA-IL1b-Rev. Therefore, we performed immunoprecipitation experiments with polyclonal IL1bR-specific antibodies using lysates of metabolically labelled CEFs infected with MVA, MVA-DIL1bR or MVA-IL1b-Rev (Fig. 2c) . The antiserum precipitated a specific protein of approximately 45 kDa from cell lysates obtained after infection with wildtype or revertant MVA corresponding in size to the glycosylated product of the IL-1bR polypeptide found in vaccinia virus Western Reserve-infected cells (Alcami & Smith, 1992) . In contrast, this protein was not detected in lysates from mock-infected or MVA-DIL1bR-infected cells, demonstrating that the generated deletion mutant virus failed to produce viral IL1bR. In addition, the data suggested that the revertant virus MVA-IL1b-Rev allowed synthesis of similar amounts of IL-1bR compared with wild-type MVA, despite the fact that the IL-1bR gene had been reintroduced at a heterologous site in the viral genome.
We also wanted to assess the replicative capacity of mutant MVA-DIL1bR in comparison with wild-type MVA. After infection of CEFs, we found comparable amounts of new viral progeny being formed with almost identical kinetics during one-step (Fig. 2d) and multiple-step (Fig. 2e) virus growth. These data clearly suggested that inactivation of MVA ORF 184R did not affect the in vitro multiplication of the virus.
Avirulence of MVA-DIL1bR following high-dose respiratory infection of mice An important question was whether the inability to produce the viral IL1bR protein would influence the outcome of MVA infection in vivo. Previous work in mice with vaccinia virus Western Reserve deletion mutants revealed either enhancement of respiratory disease after intranasal infection (Alcami & Smith, 1992) or reduced virulence after intracranial infection (Spriggs et al., 1992) . The more severe respiratory infection appeared to be linked to induction of fever response and the functional activity of the viral IL1bR neutralizing IL1b as the major endogenous pyrogen (Alcami & Smith, 1996) . Therefore, we tested mutant virus MVADIL1bR following intranasal infection of mice. Severity of disease in this mouse model is well reflected by changes in body weight and the appearance of characteristic signs of illness (Williamson et al., 1990; Alcami & Smith, 1996; Drexler et al., 2003; Reading et al., 2003; Reading & Smith, 2003b) . Additionally, we wished to monitor changes in body temperature because of the possible onset of febrile reactions. We transplanted BALB/c mice with subcutaneous microchip transponders to allow computable readings, and 1 week later infected the animals with 10 8 IU MVA or MVA-DIL1bR, or with 5610 5 p.f.u replication-competent vaccinia virus CVA or 3610 4 p.f.u Western Reserve as a control. Animals were monitored daily over a period of 3 weeks (Fig. 3) . Infection of mice with MVA or mutant MVA-DIL1bR did not result in any obvious disease. In contrast, infection with the replication-competent viruses CVA and WR caused a drastic loss of body weight (Fig. 3a) and severe signs of illness, also reflected by a reduced body temperature (Fig. 3b) . In MVA-infected animals, body temperature remained stable over the observation period. Taken together, these data suggested preservation of the attenuated phenotype of MVA after deletion of the IL1bR gene from its genome.
Early immune response induced by vaccination with MVA-DIL1bR
In the following experiments, we wished to assess the possible influence of deletion of the immunomodulatory IL1bR gene on MVA immunogenicity. First, we vaccinated HLA-A*0201-transgenic mice (HHD) with a single dose of MVA, deletion mutant or revertant virus and monitored the induction of vaccinia virus-specific CD8 + T-cell responses directly ex vivo in the acute phase of the immune response using the orthopoxvirus-specific HLA-A*0201-restricted peptide epitope VP35#1 (Drexler et al., 2003) . By FACS analysis of freshly prepared splenocytes from vaccinated animals, we were able to detect 0?4-2?45 % activated CD8 + T cells after immunization with MVA-DIL1bR, whereas in animals inoculated with MVA or revertant virus, levels of IFN-c-releasing CD8 + T cells ranged from 0?16 to 0?82 %. We analysed 12 individual mice per group for VP35#1-specific T-cell induction. However, the difference between the groups of vaccinees with regard to higher levels of T-cell immunogenicity elicited by MVA-DIL1bR (Fig. 4) was not statistically significant (P=0?07).
MVA-DIL1bR vaccination improves the T-cell memory response and long-term protective capacity
The mature form of the inflammatory cytokine IL1b has multiple effects in vivo, as revealed by the study of mice deficient for different components of the IL1 system (Sims, 2002 ). An active area of ongoing research on IL1 function is to elucidate the likely importance of this cytokine in protective T-cell immunity, including activation of professional antigen-presenting cells and memory T cells (Khayyamian et al., 2002; Iwasaki, 2003) . To investigate whether inactivation of viral IL1bR influenced the formation of memory T-cell responses, we vaccinated groups of HHD mice once with 10 8 IU MVA-DIL1bR, MVA or MVA-IL1b-Rev and monitored the presence of virus-specific T cells for more than 6 months after this primary immunization. We detected clearly higher levels of approximately 1?7 % VP35#1-reactive and IFN-c-releasing splenic CD8
+ memory T cells in MVADIL1bR-immunized animals compared with vaccination with non-recombinant MVA or MVA-IL1b-Rev, which resulted in approximately 0?4 and 0?5 % epitope-specific IFN-c-secreting CD8 + T cells, respectively (Fig. 5a ). This difference in favour of MVA-DIL1bR vaccination was statistically significant (P<0?005) and, interestingly, splenocytes from vaccinees of this group also contained significantly higher amounts of total vaccinia-specific CD8 + memory T cells (P<0?05; Fig. 5a ).
To monitor whether the different levels of memory T-cell responses coincided with alterations in protection, we challenged HHD mice by intranasal inoculation of 10 7 p.f.u vaccinia virus Western Reserve following vaccination with a single intraperitoneal inoculation of 10 8 IU MVA-DIL1bR or MVA more than 6 months previously (Fig. 5b) . In mockvaccinated control animals, infection resulted in the onset of respiratory disease, weight loss and death within 8 days of challenge. Mice inoculated with wild-type MVA were also affected by respiratory illness and substantial loss of body weight, although these animals were partially protected, since three of five mice in this group survived the challenge infection. Notably, all five animals receiving the MVADIL1bR vaccine were protected from challenge infection during a 3-week observation period, an outcome that was also reflected in a much lower level of weight loss and illness observed in this group (data not shown). This result implied that vaccination with MVA-DIL1bR could indeed have an influence on the durability of protective immunity.
The HHD mouse model allows convenient analysis of epitope-specific HLA-A*0201-restricted CD8 + T-cell responses; however, possibly because of their knockout phenotype for mouse MHC class I, these mice develop unusually low numbers of total CD8 + T cells (Pascolo et al., 1997) . As this phenotype might influence the analysis of total vaccinia-specific T-cell responses, we also assessed the number of total CD8
+ memory T cells induced by MVADIL1bR or MVA after vaccination of normal C57BL/6 mice ( Fig. 6a) . Again, in comparison with conventional MVA vaccination, we found significantly (P=0?003) higher numbers of vaccinia-specific CD8 + T cells in animals immunized with MVA-DIL1bR. These data strongly suggested an improved capacity of MVA-DIL1bR to elicit or maintain vaccinia virus-specific CD8 + T-cell memory.
To investigate the long-term efficacy of MVA-DIL1bR immunization in more detail, we decided to test the vaccines in the well-established challenge model using nontransgenic BALB/c mice (Alcami & Smith, 1992) . We chose intranasal vaccination, as this route of immunization of mice results in lower levels of circulating virus-specific antibodies compared with intramuscular or intraperitoneal vaccination (C. Staib & G. Sutter, unpublished data; Belyakov et al., 2003) , which might be an advantage when assessing the potential protective capacity of T-cell immunity. We inoculated groups of BALB/c mice with 10 6 and 10 7 IU MVA-DIL1bR, MVA or MVA-IL1b-Rev. Three and a half months after immunization, we subjected animals again to a respiratory infection with 10 7 p.f.u vaccinia virus Western Reserve (Fig. 6b, c) . Importantly, all mice that had received the MVA-DIL1bR vaccine survived the challenge and animals in the group vaccinated with 10 7 IU MVA-DIL1bR demonstrated on average <13 % reduction in body weight (Fig. 6b) and only mild signs of illness (Fig. 6c) . In contrast, there was no protection from severe disease, resulting in death of all the animals, after inoculation with 10 6 IU MVA or MVA-IL1b-Rev vaccine (Fisher's exact test, P=0?029). While vaccination with a higher dose (10 7 IU) of MVA or MVA-IL1b-Rev prevented death, animals in these groups showed a ¢20 % mean weight loss (Fig. 6b) and enhanced signs of disease (Fig. 6c) .
DISCUSSION
The MVA ORF 184R encodes a vaccinia virus soluble receptor for IL1b with the proposed function of blocking inflammatory and febrile host responses to infection. The removal of putative immune evasion genes from viral genomes is a promising approach to elucidate further the roles of these regulatory virus proteins in the in vivo virus life cycle (Alcami, 2003) . Moreover, application of this research to enable a virus such as MVA to be suitable for use as a (recombinant) live viral vaccine may lead directly to second-generation vaccines with rationally improved properties.
Despite using molecular engineering techniques allowing precise mutagenesis (Staib et al., 2000 , the resulting phenotypes of mutant viruses are unpredictable, and inactivation of the MVA IL1bR gene may serve as further example. Our finding that inactivation of the 184R ORF had no impact on the in vitro replicative capacity of the MVA mutant virus was not surprising, since growth deficiencies have not been reported with corresponding mutants derived from vaccinia virus Western Reserve (Alcami & Smith, 1992 ). Yet the capacity for high-level amplification is of the utmost importance for a virus to be used in vaccine production. Additionally, it should be noted that, with another MVA mutant defective in expression of the viral IFN response gene E3L, we recently found a very unexpected host range phenotype in CEFs, the preferred cell type for MVA vaccine production (Hornemann et al., 2003) .
In further experiments, we characterized the in vivo properties of MVA-DIL1bR. In vivo, the removal of an immunomodulator such as the viral IL1bR could have different consequences. On the one hand, it was possible that an unhampered IL1b activity elicited by infection with MVA-DIL1bR would have triggered strong inflammation reactions and febrile responses that resulted in adverse effects of vaccination. On the other hand, we speculated that IL1b action could be locally restricted and might influence the potency of MVA immunization in an adjuvant-like manner. Following intranasal infection of BALB/c mice with MVA-DIL1bR, we did not detect signs of respiratory illness, despite using high-dose inoculations and the fact that this mouse model system appears to be particularly suitable to assess potential pathogenic consequences of inflammatory responses to viral infection (Alcami & Smith, 1996; Reading et al., 2003; Reading & Smith, 2003a) . These findings confirmed that the avirulent phenotype of MVA had been conserved, even after the removal of IL1bR as a vaccinia viral factor having the potential to attenuate the pathogenicity of infection. Maintenance of attenuation is of utmost importance, especially with regard to MVA vaccine development, and may be a consequence of the particular MVA genotype, with other vaccinia virus regulatory or immunomodulatory genes being fragmented or deleted (Antoine et al., 1998) . Alternatively, it could be that the disease enhancement observed with vaccinia virus IL1bR deletion mutants requires active in vivo replication of the virus after intranasal infection. As there is good recent evidence confirming that MVA is unable to replicate in vivo in mice (Ramirez et al., 2000) or macaques (Stittelaar et al., 2001) , our data might suggest that transient one-step infection with MVA-DIL1bR is simply not sufficient to result in IL1b activities inducing adverse systemic fever or inflammation reactions.
In first-vaccination experiments, we found a slight benefit of MVA-DIL1bR immunization when monitoring for acute vaccinia virus epitope-specific T-cell responses. The H3L gene product-derived epitope VP35#1 is the target of an immunodominant HLA-A*0201-restricted T-cell specificity and can be used to examine the induction of virus-specific CD8 + T cells in an epitope-specific manner (Di Nicola et al., 2003; Drexler et al., 2003) . In contrast, bulk analysis of total vaccinia virus-specific responses can provide a representative picture based on a multitude of different T-cell specificities, but might not allow us to assess subtle changes in the activation of single T-cell populations. Suspecting a possible effect on T-cell activation, we opted also to assess VP35#1-specific T-cell memory responses, which we had previously found detectable for more than 6 months after vaccination of HLA-A*0201-transgenic mice (Drexler et al., 2003) . Indeed, we observed a significant enhancement of VP35#1-specific T-cell responses after vaccination with MVA-DIL1bR (P<0?005). We noticed for the first time a significantly increased total CD8 + T-cell response in transgenic HHD mice (P<0?05) and, more importantly, we further corroborated this result following vaccination of non-transgenic mice (P=0?003) harbouring a bona fide pool of CD8 + T cells and allowing for higher variety of MHC class I-presented peptide epitopes in comparison with HHD mice. These additional findings appeared to confirm the long-term beneficial effect of MVA-DIL1bR immunization. In addition, we found higher protective capacities against lethal respiratory challenge with vaccinia virus Western Reserve in both transgenic HHD and normal mice.
How can the enhanced vaccine efficacy in the context of IL1b function be explained? Interestingly, results from two recent studies investigating Leishmania major infection of susceptible and resistant mice suggested that the ability of dendritic cells (DCs) to secrete IL1a or IL1b is specifically associated with the induction of protective Th1 immunity (Filippi et al., 2003; Von Stebut et al., 2003) . In addition, there is recent evidence for IL1b being an essential mediator of Fas-ligation-induced maturation of murine DCs (Guo et al., 2003) . The same work demonstrated that maturation of murine DCs could be completely abrogated by the use of IL1b-neutralizing antibodies, which may function in a similar manner as would be expected with the soluble vaccinia virus IL1bR molecule. Therefore, the lack of IL1b neutralization following vaccination with MVA-DIL1bR may lead to improved functionality of DCs to serve as antigen-presenting cells, which might result in better T-cell memory responses.
Similarly, it has been shown that stimulation of endothelial cells with IL1b resulted in human inducible costimulator-ligand-mediated activation of memory T cells (Khayyamian et al., 2002) . Such activity of IL1b might be the functional basis for our finding that vaccination with MVA-DIL1bR appeared predominantly to improve memory T-cell responses, suggesting that the viral IL1bR could have a specific role in abrogating anti-viral memory T-cell responses. This appears alluring in view of recent data either demonstrating an increased persistence of CD4
+ compared with CD8 + T cells upon analysis of vaccinia virus-specific memory T cells in humans (Amara et al., 2004) or suggesting that recombinant poxvirus vaccines may potently amplify peak but not necessarily memory T-cell responses following vaccination experiments in the human simian immunodeficiency virus/rhesus macaque model (Santra et al., 2004) .
In summary, our analysis recommends deletion of the viral IL1bR gene as a first step towards the development of a new generation of MVA-based vaccines. High virus titres were obtained following in vitro propagation of the deletion mutant MVA-DIL1bR, and the avirulent phenotype of MVA was well conserved in MVA-DIL1bR, even after highdose in vivo infection. Our finding of improved vaccine properties of MVA-DIL1bR is particularly promising, since it demonstrates for the first time the possibility of obtaining more efficacious MVA vaccines through rational genetic engineering.
